Journal
JOURNAL OF DERMATOLOGY
Volume 48, Issue 2, Pages 140-151Publisher
WILEY
DOI: 10.1111/1346-8138.15730
Keywords
atopic dermatitis; corticosteroid; delgocitinib; dupilumab; tacrolimus
Categories
Ask authors/readers for more resources
The goal of treating atopic dermatitis is to achieve and maintain mild symptoms or symptom-free state. Topical therapy is the basis, but systemic therapies like dupilumab are needed for moderate to severe cases, offering high efficacy and fewer adverse reactions.
The goal of a treatment regimen for atopic dermatitis is to reach and maintain a state where the patient exhibits mild symptoms or an absence of symptoms, and the patient should not experience disturbance during daily activities. The basis of a treatment regimen for atopic dermatitis is topical therapy, and currently there exist topical corticosteroids, tacrolimus and delgocitinib. Using these, proactive therapy is performed as maintenance therapy after remission induction therapy. However, in cases of moderate to severe atopic dermatitis, topical drugs alone cannot induce remission and systemic therapies such as cyclosporin, ultraviolet therapy, and dupilumab should be used in combination. In particular, dupilumab has many advantages such as high efficacy, relatively few adverse reactions, and ease of use in elderly patients with severe atopic dermatitis. In this review, we present a treatment algorithm for atopic dermatitis that emphasizes the importance of maintaining remission after induction of remission, and summarizes the characteristics of current medication therapy for atopic dermatitis in Japan.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available